This study characterizes the clinical and molecular features of KRAS-mutated Renal Cell Carcinoma (RCC), identifying three distinct subtypes, which arise from different cells of origin and exhibit diverse genomic alterations and metabolic profiles. Here, KRAS is linked to hereditary clear cell renal cell carcinoma.